A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta
- PMID:15679068
- DOI: 10.1515/jpem.2005.18.1.43
A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta
Abstract
Bone mineral density and fracture rates in children with osteogenesis imperfecta improve with intravenous bisphosphonates. The efficacy of oral bisphosphonates has not been established. This report is an analysis of an open-label, prospective, randomized clinical trial of oral compared to intravenous bisphosphonate medications in children with osteogenesis imperfecta. Children were stratified according to bone age, pubertal stage, and type of osteogenesis imperfecta and then randomized to receive intravenous pamidronate, 3 mg/kg over 3 days every 4 months, or oral alendronate 1 mg/kg, from a minimum of 10 mg to a maximum of 20 mg daily. The primary efficacy outcome was change in bone mineral density. Secondary outcomes included change in biomarkers of bone turnover, fracture incidence, and growth rate. Ten children were randomized (6 oral and 4 intravenous). Two other children were assigned to intravenous treatment due to chronic abdominal pain. In each group, three patients had type III/IV osteogenesis imperfecta, while three had type I. All 12 children completed 8 months of therapy; nine completed 12 months. Bone mineral density increased in both oral and intravenous groups equally and beyond that expected with normal growth. All children had a decrease in biochemical markers of bone turnover. Linear growth showed a moderate increase above that for age. There was a non-significant decrease in fracture incidence in both groups.
Similar articles
- Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.DiMeglio LA, Peacock M.DiMeglio LA, et al.J Bone Miner Res. 2006 Jan;21(1):132-40. doi: 10.1359/JBMR.051006. Epub 2005 Oct 17.J Bone Miner Res. 2006.PMID:16355282Clinical Trial.
- Bisphosphonate therapy for osteogenesis imperfecta.Dwan K, Phillipi CA, Steiner RD, Basel D.Dwan K, et al.Cochrane Database Syst Rev. 2014 Jul 23;(7):CD005088. doi: 10.1002/14651858.CD005088.pub3.Cochrane Database Syst Rev. 2014.Update in:Cochrane Database Syst Rev. 2016 Oct 19;10:CD005088. doi: 10.1002/14651858.CD005088.pub4.PMID:25054949Updated.Review.
- Bisphosphonate therapy for osteogenesis imperfecta.Dwan K, Phillipi CA, Steiner RD, Basel D.Dwan K, et al.Cochrane Database Syst Rev. 2016 Oct 19;10(10):CD005088. doi: 10.1002/14651858.CD005088.pub4.Cochrane Database Syst Rev. 2016.PMID:27760454Free PMC article.Review.
- Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.DiMeglio LA, Ford L, McClintock C, Peacock M.DiMeglio LA, et al.Bone. 2004 Nov;35(5):1038-45. doi: 10.1016/j.bone.2004.07.003.Bone. 2004.PMID:15542028Clinical Trial.
- Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C.Shapiro JR, et al.Calcif Tissue Int. 2010 Aug;87(2):120-9. doi: 10.1007/s00223-010-9383-y. Epub 2010 Jun 11.Calcif Tissue Int. 2010.PMID:20544187Clinical Trial.
Cited by
- Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis.Ringe JD.Ringe JD.Patient Prefer Adherence. 2010 Jul 21;4:231-45. doi: 10.2147/ppa.s10917.Patient Prefer Adherence. 2010.PMID:20694183Free PMC article.
- Pharmacological interventions for pain in children and adolescents with life-limiting conditions.Beecham E, Candy B, Howard R, McCulloch R, Laddie J, Rees H, Vickerstaff V, Bluebond-Langner M, Jones L.Beecham E, et al.Cochrane Database Syst Rev. 2015 Mar 13;2015(3):CD010750. doi: 10.1002/14651858.CD010750.pub2.Cochrane Database Syst Rev. 2015.PMID:25768935Free PMC article.Review.
- Calcium supplementation for improving bone mineral density in children.Winzenberg TM, Shaw K, Fryer J, Jones G.Winzenberg TM, et al.Cochrane Database Syst Rev. 2006 Apr 19;2006(2):CD005119. doi: 10.1002/14651858.CD005119.pub2.Cochrane Database Syst Rev. 2006.PMID:16625624Free PMC article.Review.
- Effect of bisphosphonates on the rapidly growing male murine skeleton.Zhu ED, Louis L, Brooks DJ, Bouxsein ML, Demay MB.Zhu ED, et al.Endocrinology. 2014 Apr;155(4):1188-96. doi: 10.1210/en.2013-1993. Epub 2014 Jan 14.Endocrinology. 2014.PMID:24422540Free PMC article.
- Omics Profiling of S2P Mutant Fibroblasts as a Mean to Unravel the Pathomechanism and Molecular Signatures of X-LinkedMBTPS2 Osteogenesis Imperfecta.Lim PJ, Marfurt S, Lindert U, Opitz L, Ndarugendamwo T, Srikanthan P, Poms M, Hersberger M, Langhans CD, Haas D, Rohrbach M, Giunta C.Lim PJ, et al.Front Genet. 2021 May 21;12:662751. doi: 10.3389/fgene.2021.662751. eCollection 2021.Front Genet. 2021.PMID:34093655Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical